Lecanemab injection market to grow to $6.63B by 2030, driven by early Alzheimer's diagnosis and aging population

The global lecanemab injection market is projected to grow from $3.07 billion in 2026 to $6.63 billion by 2030, fueled by increased early-stage Alzheimer's diagnosis, FDA approvals, and expanded reimbursement policies. This growth is supported by innovations in monoclonal antibody therapies and rising global aging populations, especially in North America and Asia-Pacific. Key players like Eisai are advancing treatments, while regional challenges like tariffs encourage local manufacturing. The market outlook highlights lecanemab as a crucial treatment to slow cognitive decline in Alzheimer's patients, with expanding adoption expected worldwide.